Posted on November 1, 2018 by Sitemaster
We have recently learned that Medicare will be covering the costs of the Oncotype DX AR-V7 Nucleus Detect™ test for patients with metastatic, castration-resistant prostate cancer (mCRPC) as of December 10, 2018. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: AR-V7, Genomic Health, Oncotype, test | 4 Comments »
Posted on February 27, 2018 by Sitemaster
According to a media release issued yesterday, Genomic Health has now made available a commercial test for risk of the AR-V7 mutation in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: AR-V7, genomic, health, Oncotype, test | 3 Comments »
Posted on April 7, 2017 by Sitemaster
According to an article yesterday on Cancer Therapy Advisor, testing for circulating tumor cell (CTC)-based androgen receptor splice variant-7 (AR-V7) has now been validated as a prognostic test for men with castration-resistant prostate cancer (CRPC) receiving hormone therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: AR-V7, prognosis, test | 4 Comments »
Posted on January 8, 2016 by Sitemaster
In a statement from Tokai Pharmaceuticals, the company has provided additional information about the clinical development of the investigational drug galeterone in treatment of metastatic, castration resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: AR-V7, castration-resistant, galeterone, metastatic | Leave a comment »
Posted on June 24, 2015 by Sitemaster
According to information released earlier today by Tokai Pharmaceuticals, the company has started to enroll patients with AR-V7-positive, metastatic, castration-resistant prostate cancer (mCRPC) into a randomized Phase III clinical trial of treatment with galeterone. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: AR-V7, castration-resistant, galeterone, mCRPC, metastatic | 10 Comments »
Posted on November 20, 2014 by Sitemaster
According to a report in The ASCO Post last night, the investigational drug galeterone may have significant clinical activity against a specific subtype of castration-resistant prostate cancer (CRPC) known as AR-V7. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: AR-V7, castration-resistant, CRPC, galeterone, metastatic | 1 Comment »
Posted on September 4, 2014 by Sitemaster
We have previously commented on early reports that prostate cancer patients carrying the androgen receptor subtype known as AR-V7 (the “isoform” encoded by splice variant 7) exhibit a high level of resistance to treatment with both enzalutamide (Xtandi) and abiraterone acetate (Zytiga). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, AR-V7, enzalutamide, resistance | Leave a comment »
Posted on April 8, 2014 by Sitemaster
According to a media release issued by the American Association for Cancer Research (AACR), it may be possible to identify some men with advanced prostate cancer who are highly likely to be resistant to treatment with enzalutamide. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, AR-V7, castration-resistant, enzalutamide, mCRPC, metastatic | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 